Kenichi Nagai
Chief Executive Officer chez BRIGHTPATH BIOTHERAPEUTICS CO., LTD.
Fortune : 106 248 $ au 31/03/2024
Profil
Kenichi Nagai currently works at BrightPath Biotherapeutics Co., Ltd., as President, CEO & Representative Director from 2011, KORTUC, Inc., as Outside Director from 2019, and Advanced.Immunotherapy Co., Ltd., as President & Representative Director from 2016.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2023 | 240 000 ( 0,34% ) | 106 248 $ | 31/03/2024 |
Postes actifs de Kenichi Nagai
| Sociétés | Poste | Début |
|---|---|---|
| BRIGHTPATH BIOTHERAPEUTICS CO., LTD. | Chief Executive Officer | 01/01/2009 |
| Advanced.Immunotherapy Co., Ltd. | President | 01/12/2016 |
KORTUC, Inc.
 KORTUC, Inc. Medical SpecialtiesHealth Technology KORTUC, Inc. develops sensitizers for radiotherapy. The company was founded on October 5, 2015 and is headquartered in Tokyo, Japan. | Director/Board Member | 01/03/2019 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BRIGHTPATH BIOTHERAPEUTICS CO., LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
KORTUC, Inc.
KORTUC, Inc. Medical SpecialtiesHealth Technology KORTUC, Inc. develops sensitizers for radiotherapy. The company was founded on October 5, 2015 and is headquartered in Tokyo, Japan. | Health Technology |
| Advanced.Immunotherapy Co., Ltd. |
